The integration of targeted agents into systemic therapy of metastatic colorectal cancer

Arnold, Dirk; Siewczynski, R.; Schmoll, H.-J.

doi:10.1093/annonc/mdl249

Cited by 8 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on antibodies were also identified in relevant publications and from listings in recent overviews (Veronese and O'Dwyer, 2004;Nygren et al, 2005;Stern and Herrmann, 2005;Arnold et al, 2006;Saunders and Iveson, 2006;Van Cutsem et al, 2006). Full reporting of final results from important clinical trials often lags behind more preliminary reports in the abstract form.…”

Section: Principles For Retrieval Of Datamentioning

confidence: 99%

“…These new agents are often designated as 'targeted drugs' and very encouraging results have been obtained if administered with combination chemotherapy. The use of monoclonal antibodies have moved into the routine health care of patients with mCRC, and in recent years a huge number of patients have received antibodies often in combination with chemotherapy (Nygren et al, 2005;Arnold et al, 2006).…”

Section: Targeted Drugs In Crcmentioning

confidence: 99%

See 1 more Smart Citation

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

Section: Principles For Retrieval Of Datamentioning

confidence: 99%

Section: Targeted Drugs In Crcmentioning

confidence: 99%

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

“…The addition of targeted agents to standard chemotherapy has the potential to significantly improve response rates and survival outcomes (Arnold, Siewczynski, & Schmoll, 2006;Cunningham et al, 2004;Giantonio et al, 2007;Hurwitz et al, 2004Hurwitz et al, , 2005Kabbinavar, Hambleton, et al, 2005, Kabbinavar, Schulz, et al, 2005Saltz et al, 2007). Studies have demonstrated that the status of the K-ras gene in the tumor is predictive of outcomes with anti-epidermal growth factor receptor (EGFR) therapies.…”

Section: Biologic Agentsmentioning

confidence: 99%

Putting Evidence Into Practice

Muehlbauer

Thorpe²,

Davis³

et al. 2009

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

This article will provide an overview of the principal toxicities associated with commonly used chemotherapy treatment regimens for metastatic colorectal cancer (mCRC) and explore the role of the oncology nurse in the management of treatment-associated toxicity. Although patients with mCRC have benefited considerably from recent therapeutic advances, the use of more complex treatment regimens has inevitably resulted in an increase in treatment-related toxicities. This can ultimately lead to dose reductions, delays, or discontinuation of therapy, which may negatively affect efficacy outcomes. Early identification and treatment of toxicities often can allow treatment to continue as planned or at a lower dose, if required. The oncology nurse is ideally positioned to assist with the timely recognition and management of side effects. This allows therapy to be continued on schedule and at the appropriate dose, enabling patients to achieve a better clinical outcome and maintain or improve their quality of life.

show abstract

Section: Biologic Agentsmentioning

confidence: 99%

Filgrastim and Pegfilgrastim Use in Patients With Neutropeni

Quirion

2009

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

Myelosuppression, the reduction of platelets and red and white blood cells, is the most common side effect of chemotherapy. Filgrastim and pegfilgrastim are used to assist recovery in patients with low white blood cell counts. This article explores the dosing, efficacy, cost, and clinical considerations of filgrastim and pegfilgrastim in neutropenia care. Increased knowledge of the medications may contribute to positive patient outcomes. As the price of hospitalization increases, prophylactic dosing of filgrastim and pegfilgrastim becomes more cost effective. In addition, clinical outcomes are improved through a reduction in length of hospital stays and the need for IV antibiotic administration.

show abstract

The integration of targeted agents into systemic therapy of metastatic colorectal cancer

Cited by 8 publications

References 27 publications

Current role of antibody therapy in patients with metastatic colorectal cancer

Current role of antibody therapy in patients with metastatic colorectal cancer

Putting Evidence Into Practice

Filgrastim and Pegfilgrastim Use in Patients With Neutropeni

Contact Info

Product

Resources

About